Literature DB >> 17698153

The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys.

Ajay Sood1, J Warren Beach, Scott J Webster, Alvin V Terry, Jerry J Buccafusco.   

Abstract

JWB1-84-1 is one of 50 tertiary amine analogs of choline synthesized with expectation that they would be high potency compounds for cytoprotection. As one of the more potent analogs in this regard, JWB1-84-1, a piperazine derivative, was selected for testing as a cognition-enhancing agent. The compound was evaluated for efficacy in Alzheimer's disease transgenic mice (B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J). A separate cohort of mice (AD Tg) were first subjected to a behavioral test battery in which the transgenic strain was compared with the wild-type strain. AD Tg mice were shown to exhibit specific deficits in the acquisition of a working memory (5-trial/session radial arm water maze, RAWM) task at a time when the animals exhibited maximal cerebral amyloid burden. JWB1-84-1 produced a dose-dependent decrease in the number of errors made by well trained AD-Tg mice the RAWM task that was maximal after the 20 microg/kg dose. Aged macaques (20-32 y) were trained to proficiency in their performance of a computer-assisted delayed matching-to-sample task. Vehicle (normal saline) or JWB1-84-1 (5-150 microg/kg, i.m.) was administered 10 min before the initiating of testing. On average, JWB1-84-1 treatment significantly improved task accuracy after all but the lowest dose. The maximal degree of improvement was attained after animals received the 100 microg/kg dose. The drug's effects were restricted primarily to Medium and Long delay trials - the most difficult portions of the task, which were improved by up to 18% above control. In young macaques JWB1-84-1 treatment also significantly reversed the decrements in task accuracy associated with the random presentation of a task distractor. Thus JWB1-84-1exhibits the potential for treating the cognitive symptoms associated with neurodegenerative diseases and attention deficit disorders. Its cytoprotective action might also work to slow the progression of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698153     DOI: 10.1016/j.neuropharm.2007.06.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  21 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

Review 3.  Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.

Authors:  Alvin V Terry; Michael W Decker
Journal:  Biochem Pharmacol       Date:  2011-06-12       Impact factor: 5.858

Review 4.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

5.  Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice.

Authors:  John A Kennard; Fiona E Harrison
Journal:  Behav Brain Res       Date:  2014-02-05       Impact factor: 3.332

6.  Protective effects of a piperazine derivative [N-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-phenyl} carbamic acid ethyl ester] against aluminium-induced neurotoxicity: insights from in silico and in vivo studies.

Authors:  Poonam Meena; Apra Manral; Vikas Saini; Manisha Tiwari
Journal:  Neurotox Res       Date:  2014-11-18       Impact factor: 3.911

7.  Therapeutics for cognitive aging.

Authors:  Diana W Shineman; Timothy A Salthouse; Lenore J Launer; Patrick R Hof; George Bartzokis; Robin Kleiman; Victoria Luine; Jerry J Buccafusco; Gary W Small; Paul S Aisen; David A Lowe; Howard M Fillit
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

8.  Temporal progression of Alzheimer's disease in brains and intestines of transgenic mice.

Authors:  Gunjan D Manocha; Angela M Floden; Nicole M Miller; Abbie J Smith; Kumi Nagamoto-Combs; Takashi Saito; Takaomi C Saido; Colin K Combs
Journal:  Neurobiol Aging       Date:  2019-06-13       Impact factor: 4.673

Review 9.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

Review 10.  Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.

Authors:  Jerry J Buccafusco; J Warren Beach; Alvin V Terry
Journal:  J Pharmacol Exp Ther       Date:  2008-11-20       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.